BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Peptide bioavailability has been significantly enhanced in rec
 ent years\, evidenced by Pfizer developing an optimized formulation for i
 ts oral GLP-1 drug danuglipron\, AbbVie buying out Nimble Therapeutics fo
 r its oral peptide assets and J and J advancing development of its IL-23 
 receptor antagonist peptide to address the high unmet need for a durable 
 oral option. Additionally\, innovative excipient and delivery approaches 
 are making oral administration of peptides a clinical reality\, but bottl
 enecks remain.\n\nReturning to Boston as your premier industry-dedicated 
 forum\, the 2nd Peptide Formulation and Delivery Innovation Summit addres
 ses how to overcome unique formulation challenges and accelerate innovati
 ve delivery technology applications to progress peptide-based therapeutic
  pipelines towards patients and commercialization.\n\nAs peptide-based th
 erapeutics continue to be touted as the Goldilocks drug modality and are 
 set to seriously disrupt the drug development landscape\, join this forum
  to stay ahead of the curve:\n\nLearn about state-of-the-art peptide form
 ulation technologies such as permeation enhancers\, nanoparticle encapsul
 ation and structural modification abilities\n\nOvercome technical and sci
 entific challenges in optimizing peptide stability and bioavailability fo
 r oral\, injectable\, inhaled and intra-dermal formulations\n\nBuild part
 nerships with excipient and ingredient providers\, device testing service
 s\, pre-clinical models and CDMOs that are well-versed in optimizing nove
 l or reformulated peptide drugs\, and scaling up manufacturing without co
 mpromising drug safety or efficacy\n\nBe part of the industry-dedicated p
 eptide formulation and delivery community that is spearheading innovative
  peptide formulation and delivery technologies to enhance peptide drug co
 nstitution without impacting efficacy\, ensure patient adherence and acce
 lerate peptide drug product towards approval.\n\nURLs:Tickets: https://go
 .evvnt.com/2927655-2?pid=185Brochure: https://go.evvnt.com/2927655-3?pid=
 185\n\nTime: 8:00 AM - 5:00 PM\n\nPrices:Drug Developer Pricing - Confere
 nce and 1 Workshop: USD 3598.00\,Drug Developer Pricing - Conference Only
 : USD 2999.00\,Academic Pricing - Conference and 1 Workshop: USD 3098.00\
 ,Academic Pricing - Conference Only: USD 2499.00\,Solution Provider Prici
 ng - Conference and 1 Workshop: USD 4398.00\,Solution Provider Pricing - 
 Conference Only: USD 3699.00\n\nSpeakers: Ankur Sharma Senior Formulation
  and Development Scientist Hyalo Technologies\, Chen Liang Senior Scienti
 st Novo Nordisk\, Dhanashree Surve Assistant Scientist University of Miam
 i Miller School of Medicine\, Gilles Divita Co-Founder and Chief Executiv
 e Officer Divincell / Aanastra\, Kinkini Roy Associate Director - Drug Pr
 oduct Development Aviceda Therapeutics\, Mi Cai Associate and Registered 
 Patent Attorney Foley Hoag\, Mike Davies Founder and Chief Executive Offi
 cer Carocell Bio\, Mridula Dogra Senior Advisor Eli Lilly\, Nitin Joshi A
 ssistant Professor Brigham and Women's Hospital\, Harvard Medical School\
 , Patricia Grasso Professor of Medicine\, Neuroscience and Experimental T
 herapeutics Albany Medical College\, Peter Knauer Vice President of CMC X
 eris Pharmaceuticals\, Riet Dams Global Head of Pharmaceutical Product De
 velopment and Supply Johnson and Johnson\, Rose Kanasty Vice President of
  Platform Development Lyndra Therapeutics\, Ruzica Kolakovic Senior Princ
 ipal Scientist\, Drug Product Development Scientific Integrator Johnson a
 nd Johnson\, Sinead Bleiel Founder AnaBio Technologies\, Siyuan Huang Sen
 ior Director - Product Delivery\, CMC Project Management Eli Lilly\, Stua
 rt Madden Chief Scientific Officer Neurelis\, Tarik Soliman Founder and C
 hief Executive Officer Extend Biosciences\, Vincent Jannin Director\, R a
 nd D and Head of Innovaform™ Accelerator Lonza\, Yuhan Lee Co-Founder and
  Assistant Professor AltrixBio and Harvard Medical School\, Zhigao Niu In
 novation Lead and Senior Scientist Novo Nordisk\n
DTEND:20250626T170000
DTSTAMP:20260512T220333Z
DTSTART:20250624T080000
LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac
 husetts\, 02128\,
SEQUENCE:0
SUMMARY:Peptide bioavailability has been significantly enhanced in recent 
 years\, evidenced by Pfizer developing an optimized formulation for its o
 ral GLP-1...
UID:02276083-fed6-44ff-8d14-1187fa905f84
END:VEVENT
END:VCALENDAR